OpGen, Inc. (NASDAQ:OPGN)’s share price shot up 4.1% during trading on Friday . The company traded as high as $0.31 and last traded at $0.31. 1,525,836 shares traded hands during mid-day trading, a decline of 8% from the average session volume of 1,653,190 shares. The stock had previously closed at $0.30.

A number of research firms have commented on OPGN. Zacks Investment Research lowered shares of OpGen from a “buy” rating to a “hold” rating in a research report on Saturday, August 26th. HC Wainwright set a $1.00 price target on shares of OpGen and gave the company a “buy” rating in a research report on Wednesday, August 9th. Finally, Dawson James restated a “buy” rating on shares of OpGen in a research report on Monday, June 19th.

The company’s 50-day moving average price is $0.29 and its 200-day moving average price is $0.71. The stock’s market cap is $15.67 million.

In other news, Chairman Jven Capital, Llc bought 1,875,000 shares of the firm’s stock in a transaction on Tuesday, July 18th. The shares were purchased at an average cost of $0.40 per share, with a total value of $750,000.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Timothy C. Dec bought 65,000 shares of the firm’s stock in a transaction on Tuesday, July 18th. The stock was purchased at an average cost of $0.40 per share, for a total transaction of $26,000.00. Following the completion of the acquisition, the chief financial officer now owns 118,966 shares in the company, valued at $47,586.40. The disclosure for this purchase can be found here. 53.27% of the stock is owned by company insiders.

A hedge fund recently raised its stake in OpGen stock. Vanguard Group Inc. raised its position in OpGen, Inc. (NASDAQ:OPGN) by 1.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 342,860 shares of the medical research company’s stock after buying an additional 5,500 shares during the quarter. Vanguard Group Inc. owned about 1.25% of OpGen worth $219,000 at the end of the most recent quarter. 8.13% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was posted by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.dailypolitical.com/2017/09/08/opgen-inc-opgn-shares-up-4-1.html.

About OpGen

OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.